90Y labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas

The monoclonal antibody (mAb) MOv18 binds the membrane alpha isoform of the folate receptor (FR) which is overexpressed in human ovarian carcinoma cells. Exploiting the targeting capacity of this mAb, we developed and preclinically validated a protocol for the stable labeling of the mAb with Y-90, an isotope which has shown promise in cancer radioimmunotherapy. MOv18 was derivatized with the stable macrocyclic ligand p-isothiocyanatobenzyl-1,4,7,10-tetraazacyclododecane1,4,7,10- tetraacetic acid (BzDOTA). MOv18-Bz-DOTA conjugates were labeled with Y-90 or In-111 under metal-free and good laboratory practice conditions. At the optimal Bz-DOTA/mAb derivatization ratio of 4 - 5, conjugates maintained binding activity up to 6 months, were efficiently labeled with Y-90 or In-111 ( mean labeling yield 85 and 64%, associated to a final mean specific activity of 74 and 37 MBq/mg) and displayed a mean immunoreactivity of 60 and 58%, respectively. The radiolabeled preparations were stable in human serum, with > 97% radioactivity associated to mAb at 48 h after labeling. The ability of Y-90- and In-111-MOv18 to localize FR on tumors in vivo was analyzed in nude mice bearing tumors induced by isogenic cell lines differing only in the presence or absence of the relevant antigen [A431FR (FR-positive) and A431tMock (FR-negative)]. In vivo biodistribution in organs other than tumor was comparable in non-tumor-, A431tMock- and A431FR-bearing mice, whereas the median tumor uptake of the radiolabeled reagents, expressed as area under the curve (AUC) and maximum uptake (U-max), was significantly higher ( sixfold to sevenfold) in A431FR than in A431tMock tumors (P= 0.0465 and P= 0.0332, respectively). Mean maximum uptake (% ID/ g) for Y-90-MOv18 was 53.7 and 7.4 in A431FR and A431tMock respectively; corresponding values for In-111-Mov18 were 45.0 and 11.3. These data demonstrate the feasibility of Y-90-labeling of MOv18 without compromising antibody binding ability and the immunoreagent-specific localization in vivo on FR-expressing tumors, suggesting the suitability of Y-90-MOv18 for clinical studies.